Human Multidrug resistance-associated protein 4 (ABCC4) ELISA Kit
| Product Name | Human Multidrug resistance-associated protein 4 (ABCC4) ELISA Kit |
|---|---|
| Description | ABCC4, also known as MRP4, belongs to a large family of transmembrane proteins involved in active transport of substrates out of cells. ABCC4 acts as an independent regulator of intracellular cyclic nucleotide levels and as a mediator of cAMP-dependent signal transduction to the nucleus. The insertion was attributed to 2 additional exons, designated 1a and 1b, that produced premature termination codons (PTCs). A comparison of human, monkey, and rodent ABCC4 genes revealed that these same PTC-producing exons were also highly conserved in evolution. In vitro inhibition of protein synthesis (using puromycin or anisomycin) selectively reduced nonsense-mediated mRNA decay of PTC-containing ABCC4 transcripts in all cell lines tested. This assay has high sensitivity and excellent specificity for detection of Human ABCC4. No significant cross-reactivity or interference between Human ABCC4 and analogues was observed. |
| Synonyms | RP11-74A12.1, EST170205, MOAT-B, MOATB, MRP4, ATP-binding cassette, sub-family C, member 4|bA464I2.1 (ATP-binding cassette, sub-family C (CFTR/MRP), member 4)|canalicular multispecific organic anion |
| Method | Sandwich ELISA |
| Detection Range | 0.312-20 ng/mL |
| Sensitivity | 0.115 ng/mL |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Other biological fluids. |
| Background |
ABCC4, also known as MRP4, belongs to a large family of transmembrane proteins involved in active transport of substrates out of cells. ABCC4 acts as an independent regulator of intracellular cyclic nucleotide levels and as a mediator of cAMP-dependent signal transduction to the nucleus. The insertion was attributed to 2 additional exons, designated 1a and 1b, that produced premature termination codons (PTCs). A comparison of human, monkey, and rodent ABCC4 genes revealed that these same PTC-producing exons were also highly conserved in evolution. In vitro inhibition of protein synthesis (using puromycin or anisomycin) selectively reduced nonsense-mediated mRNA decay of PTC-containing ABCC4 transcripts in all cell lines tested. |
| Supplier | Abebio |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
